Today, tech titans continue to reshape and even disrupt global pharmaceutical investments for both better healthspan and longer lifespan.

Today tech titans and billionaires continue to reshape global pharmaceutical investments for both better healthspan and longer lifespan.

We discuss, describe, and delve into the new medical sciences of longer longevity and their broader implications for stock market investments. In our modern human history since 1950, the average life expectancy worldwide has incrementally risen by 3 months to 5 months each year. The vast majority of men and women can now expect to live well beyond 70 years in many of the rich countries. This demographic mega trend reflects new medications, treatments, and therapies for many common diseases, disorders, symptoms, and other health conditions in association with old age. These diseases, disorders, and other health conditions include heart diseases, diabetes, Alzheimer’s and Parkinson’s diseases, sleep apnea and other disorders, peripheral arterial diseases, liver and kidney diseases, some sorts of cancers, non-alcoholic steato-hepatitis, knee osteoarthritis, and so forth. Many tech titans have invested heavily on high-efficacy medications, treatments, and therapies for these diseases, disorders, and other health conditions in support of both longer lifespan and substantial improvements in the health quality of life.

 

However, there are at least 2 major caveats. First, the increases in human lifespan are only incremental and so eventually confront the upper limit. Although the global number of centenarians continues to grow over time, this number seems to stretch its limit in due course. A recent Pew Research survey shows the new projection of more than 3.7 million centenarians worldwide by 2050, or almost 3 times as many centenarians per head of population as in 2015. Nonetheless, only one in 1,000 of these centenarians can live beyond 110 years, and almost no one can live beyond 120 years in modern human history. The maximum human age seems to rise at a much slower pace than the average human life expectancy does in recent decades. Second, the average healthspan, or the number of healthy vital years, may or may not keep pace with longer lifespan. For this reason, many tech titans have invested heavily in modern AI technological advancements in new medications, treatments, and therapies to support both longer lifespan and substantial health improvements in the quality of life for many men and women worldwide. Further, pharmaceutical titans have invested significantly in brand-new third-generation anti-obesity weight-loss medications primarily due to their increasingly higher efficacy and other health benefits. As many men and women now live longer lives, longer lifespan reflects a mix of clean, lean, and healthy lifestyle changes, choices, and decisions from good diet and regular exercise to smarter and better sleep, mood control, less or minimal stress, and deeper, greater, and broader social integration with family and friends. Today, new biomedical innovations, research endeavors, and capital investments help slow down and even reverse human age progression.

 

Several stock market magnates, moguls, tycoons, and key venture capitalists have been instrumental in the creation of lean startups in support of both longer lifespan and better healthspan. For instance, the serial venture capitalist and co-founder of PayPal and Facebook etc, Peter Thiel, invested a hard, high, and hefty fraction of his personal net worth in many medtech advances and lean startups in health care, precision medicine, and biotechnology. These ventures include Palantir, Women’s Healthcare Fund, Founders Fund, and Lindus Health. Specifically, Thiel invested more than $410 million in a strategic partnership between Palantir and the British National Health Service (NHS) to completely revamp the NHS patient data system. In addition, Thiel supported Recharge Capital’s $200 million Women’s Healthcare Fund to focus on high-efficacy alternative medications, treatments, and therapies for breast cancer, endometriosis, and polycystic ovary syndrome (PCOS). Through Founders Fund, Thiel invested many millions of dollars in 5 major lean startups for better biotech and medtech advances, inventions, and solutions. These major lean startups span Forward Health, Emerald, Cambrian, Counsyl, and Stemcentrx (now as part of AbbVie). In the meantime, these ventures focus on the new, non-obvious, and next-generation technical advances and medical innovations in biometric body scans, blood tests, stem cell therapies, and genetic modifications for better disease prevention. In recent years, Thiel contributed to the $6 million venture investment fund for the London company, Lindus Health, to dramatically speed up clinical trials for new medications, treatments, and therapies.

 

The Stanford co-founders of Google, Larry Page and Sergey Brin, invested heavily in better biotech, healthcare, and precision medicine too, primarily through 2 major Alphabet subsidiaries Verily and Calico. Today, Verily focuses on new medications, treatments, and therapies for dyspraxia, dyslexia, sleep apnea, insomnia, anxiety, depression, and other mental health and movement disorders. Furthermore, Verily seeks to eradicate all sorts of infectious diseases by killing insects and mosquitoes with the Zika, dengue fever, and other viruses and bacteria etc. In addition, Google DeepMind applies machine-learning algorithms and other AI-driven instruments to substantially sharpen the medical predictions of fatal diseases such as kidney and liver failures, stroke, cardiac arrest, sepsis, and pulmonary embolism.

 

Google DeepMind has built a new program, AlphaFold, from the previous success of AlphaGo in outperforming the top Go chess players worldwide. With AlphaFold, biomedical scientists help accelerate the major identification of new compounds in better clinical trials. Specifically, AlphaFold analyzes how some sequence of amino acids folds into the particular shape for some sort of protein. In essence, AlphaFold helps identify the more complex set of rules for some sequence of amino acids to fold biomedically into the same shape for some sort of protein in the human body. With tremendous success worldwide, AlphaFold accelerates and so revolutionizes the new wave of innovative drug discovery in support of smarter, faster, and better AI-driven medications, treatments, and therapies. In 2024, Google DeepMind CEO and Co-Founder Sir Demis Hassabis and DeepMind Director Dr John Jumper won the Nobel Prize in Chemistry for their recent design and development of AlphaFold for predicting the structures of different proteins from their amino acid sequences. Hassabis and Jumper shared this Nobel Prize with Dr David Baker who worked on computational protein design.

 

Many clever biomedical scientists had been trying hard to create computer models of the structural processes for folding amino acids into proteins in the human body for many decades. Just as AlphaGo trounced the best Go chess human players in recent years, AlphaFold substantially improved the best efforts of many biomedical scientists in past decades. Specifically, the shape of each protein reveals immense practical importance in terms of what the protein does alone, what other molecules can do to this protein, and the complex chemical interactions between each protein itself and its nearby and adjacent molecules and chains of amino acids. Almost all the basic structural processes of life depend on new complex chemical interactions among vital proteins, molecules, amino acid chains, and so forth. The vast majority of new drug discovery programs aim to find some sorts of molecules in support of desirable chemical interactions. Sometimes these molecules block specific protein actions, and sometimes these molecules encourage and stimulate specific protein actions. Before AlphaFold, more than 50 years of structural biology had produced several hundred thousand reliable protein structures through the traditional X-rays and nuclear-magnetic resonance techniques. AlphaFold and its closest rivals and competitors, ESMFold by Meta AI, OmegaFold by Helixon, and RoseTTAFold by Baker Lab, have provided more than 600 million sharp and accurate predictions of protein shapes for AI-driven medications, treatments, and therapies. Today, these deep machine-learning algorithms and Gen AI models, robots, and instruments etc continue to accelerate new technological advancements in structural biology.

 

Nowadays, Larry Page and Sergey Brin drive and steer Calico’s scientific research endeavors to build up new longitudinal patient databases. The next steps can help reveal the mainstream medical mechanisms for human age progression. In close collaboration with top institutions such as Harvard Medical School and Mayo Clinic, Calico delves into how biomedical doctors, scientists, and other health specialists can use new medications, treatments, and therapies to help slow down the natural course of human age progression. Today, the Food and Drug Administration (FDA) still does not recognize old age as a disease state and therefore as a proper target for treatment in America. Despite this current obstacle, Calico now navigates many health factors, forces, and biochemical interactions for medical intervention. These best efforts can combine to help each patient return to the new normal steady state. Even though these best efforts cannot reverse human age progression, these best efforts can perhaps help extend human healthspan dramatically in due course.

 

The founder and serial entrepreneur of Amazon, Jeff Bezos, invested in numerous companies in support of early cancer detection (Grail), immunotherapy (Juno), and anti-aging research (Unity) primarily through his venture fund, Bezos Expeditions. In recent years, the CEO and co-founder of OpenAI, Sam Altman, backed the $1 billion round for the AI-driven healthcare startup, Retro Biosciences, in support of new medications, treatments, and therapies for common diseases, disorders, and other health ailments. Through the Gates Foundation, Bill Gates invested heavily in new high-efficacy medications, vaccines, treatments, therapies, and healthcare services worldwide. Specifically, the Gates Foundation provides a $90 million prize for the new, non-obvious, next-generation pneumococcal conjugate vaccine (PCV). In accordance with the original prize proposal by Nobel Laureate Michael Kremer, the Gates Foundation strives to prevent pneumococcal infections by providing the new vaccine to each person at the $2.00 marginal cost. In recent years, the Gates Foundation continues to finance global biomedical research programs to eradicate HIV-AIDS, tuberculosis, polio, and malaria, especially in sub-Saharan Africa. With Quantum Biosciences, the Gates Foundation now aims to advance mRNA vaccine design, research, and mass production for efficient Covid prevention. Through the Dementia Discovery Fund, Bill Gates supports many lean-startup ventures on new medications and treatments for Alzheimer’s and Parkinson’s diseases. In addition, Gates continues to finance Foundation Medication in support of the new discovery of DNA sequences for cancer medications. Today, Bill Gates serves as one of the major investors in Ginkgo Bioworks. This biotech company helps tailor biochemical health products and medications to men and women with specific DNA sequences. We believe these resultant biomedical research developments can come to fruition in due course.

 

Beneath the forest canopy of pharmaceutical titans and startups with tech royalty, an undergrowth of lean startups continues to work on new medications, treatments, and therapies against some aspects of human age progression. The basic insight catches on of prolonging both lifespan and healthspan with some pills and potions, in addition to the more conventional baseline approach of diet, exercise, and high-quality sleep. New diagnostic tools, machines, and instruments provide the means for biomedical scientists to calculate the biological ages of both bodies and organs by comparison to actual calendar ages. In principle, this new capability allows both lifespan and healthspan studies to attain remarkable results in less than a lifetime. New gene modifications further help analyze vast amounts of gene sequence data. This new capability helps personalize new stem cells, medications, and treatments with a broader menu of therapeutic options.

 

Unlike many machines, bodies both make themselves and repair themselves. Why do human bodies age progressively with so many imperfections? Perhaps the high designer of life, natural evolution, focuses on better reproduction instead of longer lifespan. Life arises as a result of genes, development, behavior, and the broader environment. With accidents, predators, and diseases, the environment kills many creatures. Genes with health benefits that show up only over a longer lifespan than the broader environment allows in practice are not likely to perform particularly well in reproduction unless these genes provide some other health benefits. Genes that provide a fertile youth with successful reproduction are often onto a winner. There is some evidence that one variant of a specific gene in association with Alzheimer’s and Parkinson’s diseases provides reproductive advantages to young people.

 

From the evolutionary point of view of the genes, a person is a way to make further copies of the genes. In this wider view, a person’s life is a means to an end but not an end in itself. Keeping the human body’s repair mechanisms in tip-top conditions is worthwhile only if the human body gets more genes into the next generation. In this disposable soma approach, the person is a means to an end, and we abandon the life if it is no longer fit for the mainstream purpose of reproduction. This broader perspective helps explain why many diseases and other health conditions are often common in old age but relatively rare in early life. These diseases and other health conditions include Alzheimer’s and Parkinson’s diseases, diabetes, heart diseases, some sorts of cancers, retinal degeneration, osteoarthritis, and so forth.

 

Many genes have variants, also known as alleles, and all of these alleles work but may cause slightly different effects. With the genetic manipulation of lab organisms, some studies of the genes of human centenarians have identified alleles of specific genes that have been proven experimentally to prolong lifespan. These genes also result in significant improvements in the health quality of life. In recent years, these new studies can often help illuminate the natural course of human age progression. In recent years, these new studies suggest 12 hallmarks of human age progression. The dirty dozen spans genomic instability, telomere attrition, epigenetic alteration, metabolic decline for nutrient energy, mitochondrion dysfunction, proteostasis loss, stem cell exhaustion, chronic inflammation, autophagy decline, dysbiosis, cellular senescence, and intercellular breakdown. We delve into the mainstream scientific progress on each of these 12 hallmarks of human age progression. The devil is in the detail. Biomedicine can be quite complex. Sometimes a biomedical intervention may perform well in more than one field. At other times, there may be trade-offs in new medications, treatments, and therapies. We discuss, describe, and delve into the biomedical sciences of both longer lifespan and smarter and better healthspan, as well as their broader implications for stock market investments.

 

When we eat and consume all essential nutrients with good proteins, vitamins, and minerals, but fewer calories, we can help ensure both better healthspan and longer lifespan in time.

Some recent empirical studies show that lab protocols provide rats, dogs, fruit flies, and worms with the essential nutrients, such as good proteins, vitamins, minerals, and so on, but substantially fewer calories, to help promote both better healthspan and longer lifespan in due course. Calories can often help measure the amount of energy that cells can get from breaking food into its biochemical components. The precise nature of this nutrient absorption is under the control of a broader range of brain pathways. In effect, these brain pathways regulate and match molecular and cellular interactions with vital energy storage from food intake. Dysfunction in these nutrient-driven pathways is one of the 12 hallmarks of human age progression.

 

Some recent top-tier biomedical lab studies show substantial successes of calorie restrictions in helping slow down the vital natural course of human age progression. When energy becomes relatively scarce within the human body, the nutrient-driven pathways pay greater attention to many molecular and cellular interactions. These brain pathways help keep each cell in better shape. Also, these pathways regulate more than one function quite often. Multiple pathways frequently help regulate vital functions within the human body. Even in the biomedical sciences of life today, the farthest-flung parts of pathways remain obscure. After all, the vast majority of brain pathways often regulate and match metabolic profiles for particular proteins, amino acid chains, cells, tissues, and molecules.

 

This regulatory power spans a broad ambit. The vital brain pathways affect the key pace at which cells break down internal structures with some ailment or impairment through autophagy. Further, these vital brain pathways help maintain the delicate internal balance of their protein content through proteostasis. Also, these vital brain pathways help accelerate the vital reproduction of mitochondria, biochemical parts and components for turning calories into some form of energy for particular protein and amino-acid actions. Autophagy, proteostasis, and mitochondrion reproduction are 3 more of the 12 hallmarks of human age progression.

 

Another brain pathway targets a particular protein, AMPK, and effectively regulates the vital reproduction of ATP, a small energy-carrying molecule often found in each mitochondrion. When the vital internal levels of this molecule decline (ATP decline), the brain pathway for the particular protein, AMPK, increases each cell’s sensitivity to insulin. In effect, the new medication for diabetes, Metformin, helps enhance this cellular sensitivity to insulin by activating the vital pathway for the particular protein, AMPK. A recent study shows that many diabetes patients who take this medication, Metformin, face a substantially lower mortality rate, not only by comparison to other diabetes patients who take none of the new medication, but also by comparison to healthy peers with no diabetes. In recent years, the American Federation for Aging Research, a not-for-profit organization, strives soon to start a long-term clinical trial of 3,000 diabetes patients for Metformin, especially for diabetes patients between 65 years old and 80 years old. This new large-scale clinical trial can help illuminate whether Metformin can help prevent heart diseases, Alzheimer’s and Parkinson’s diseases, and some kinds of cancers in old patients with diabetes.

 

The new third-generation GLP-1 medications for obesity treatment and weight loss treatment, Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, now begin to become more prevalent and more pervasive worldwide. These medications show far higher weight loss efficacy than prior first-generation and second-generation medications. The latest GLP-1 medications further show long prevalent safety track records for the treatments of diabetes, heart diseases, and several kinds of cancers. However, the current U.S. prices for these new GLP-1 medications are extremely high (about $15,000 per patient per year). In the meantime, not all people with obesity can take these new GLP-1 medications because they are now prohibitively costly and U.S. insurance coverage remains partial and incomplete. Despite these current hurdles, obstacles, and impediments for broader GLP-1 drug adoption, we now expect the global market for GLP-1 obesity and weight loss medications to grow substantially to benefit more than 1 billion patients with obesity worldwide by 2030. These GLP-1 obesity weight-loss medications not only treat, reduce, and curtail heart diseases, diabetes, some kinds of cancers, and possibly some additional diseases, disorders, and other health conditions, but also help promote both longer longevity and health improvements in the broader quality of life.

 

In recent years, the Director of the Center for Biology of Aging Research at Harvard University, Dr David Sinclair, shows in his recent lab studies that Sirtuins serve as 7 mammalian protein isoforms to regulate various physiological processes such as metabolism, stress response, and human age progression. Sirtuins can serve as potential therapeutic targets for further calorie restrictions. The recent studies show that lab protocols help substantially prolong lifespan for a variety of lab animals by stimulating the vital reproduction of Sirtuins in these lab animals. In his subsequent studies, Dr Sinclair discovers a new biochemical alternative to Sirtuins, Resveratrol, often found in the skins of red grapes. This novel chemical compound, Resveratrol, can be helpful for the current treatments of hay fever, obesity, and diabetes. Also, Resveratrol can cause positive metabolic effects in the human body by expanding blood vessels with substantially fewer blood clots. Dr Sinclair’s lean startup, Sirtris (now as part of GlaxoSmithKline (GSK)), produces these Resveratrol biochemical compounds as new derivative health products for the human body. After the recent $720 million acquisition by GSK, Sirtris continues to design new target medications, treatments, and therapies in association with metabolism and chronic inflammation in the human body.

 

Sirtuins attracted substantial attention worldwide because there had been virtually no or few similar and credible claims about longevity for many years. Their success story sets out a bright blueprint for looking into the new biochemical compounds in support of both better healthspan and longer lifespan through smarter proteostasis, metabolism, and autophagy. Subsequent studies seek to replicate the standalone success of Sirtuins, and many biomedical scientists strive to find new medications and chemical compounds for slowing down some parts, aspects, and components of human age progression.

 

 

In the medical sciences of both better healthspan and longer lifespan, the medium-term and relatively transient cellular metabolism gives old tissues a fresh capacity for self-repair. New stem-cell research developments help reshape the competitive landscape of cellular rejuvenation for many pharmaceutical titans and lean startups.

In the medical sciences of both better healthspan and longer lifespan, healthy and non-cancerous mammalian cells can reproduce themselves for only a set number of times before vital cell division ceases in due time. In the alternative steady state, cells, tissues, and molecules reach a subsequent state of senescence. For human cells, this Hayflick limit is 40 times to 60 times per lifetime. In practice, the medium-term and relatively transient cellular metabolism gives many old cells, tissues, and molecules a fresh capacity for self-repair. Cellular rejuvenation arises from several recent developments in stem-cell science. The new miraculous stem-cell methods for cellular rejuvenation slow down and even reverse the natural course of human age progression. These recent stem-cell research developments provide plausible, radical, and thorough anti-aging medications, treatments, and therapies. This new stem-cell science now needs and attracts several tech titans, billionaires, venture capitalists, and pharmaceutical jumbos with deep pockets.

 

The human body contains hundreds of different types of vital internal cells, tissues, and molecules, each with the right properties for a specific sort of function. Indeed, this differentiation helps turn on and off different sets of genes, proteins, and amino acid chains by means of many epigenetic modifications. Some of these epigenetic modifications involve biochemical alterations to some specific genomic sequences. Through these genomic sequences, biochemical interactions revolve around some specific genes, proteins, amino acid chains in subtle ways. The vital processes that sustain these critical epigenetic modifications from year to year eventually become less effective with old age. The particular patterns of DNA methylation, a chemical change to one of the molecule’s genetic letters, can help diagnose the age of each cell. In essence, stem cells can contribute to better cellular metabolism, self-repair, and rejuvenation.

 

Stem cells serve as fresh reserves for cellular rejuvenation. For some vital function, each stem cell of one specific type can be made from these fresh reverses. As one cell divides, one of the 2 progenitor stem cells sets off down a new and fresh route of epigenetic specialization. In effect, this epigenetic specialization mass-produces new stem cells of specific types. In this way, the hematopoietic stem cells in blood marrow can produce progeny in support of subsequent derivative cell rejuvenation for both white blood cells and red blood ones, the latter of which help carry, transfer, and shore up oxygen throughout the human body. To sustain this virtuous cycle of cellular rejuvenation for each lifetime, these cells need to divide more than 40 times to 60 times, the average Hayflick limit of human cell division per lifetime; otherwise, these cells would ultimately reach the new steady state of senescence.

 

Allowing stem cells to keep their vital reproduction is the task of a specific enzyme, telomerase. The physical manifestation of each cell’s descent toward the Hayflick limit recurs in key structures at the end of its chromosomes. These key structures, telomeres, serve as protective DNA caps and then progressively shorten with each cell division in association with the natural course of human age progression. Each time the chromosomes reproduce themselves to allow each individual cell to divide, the telomeres become shorter. After about 40 to 60 cell divisions, these telomeres are too short for the chromosomes to reproduce themselves. In stem cells, though, telomerase prolongs cell divisions to rebuild reasonably long and active telomeres for specific chromosomes. In this rare unique fashion, these new miraculous stem-cell methods reset the clock for cellular metabolism specifically, and for human age progression more generally. As time goes by, however, stem cells may pick up key negative epigenetic markers too. As a consequence, stem cells decline in number, in capacity, or both.

 

Some recent stem-cell studies show that it is scientifically plausible to remove key negative epigenetic markers off the DNA sequences in each cell. By administering a specific set of 4 transcription factors, or equivalently, proteins in association with specific types of genes as new blueprints for proteins, these 4 factors help strip off key negative epigenetic markers from each cell and then return the cell back to the new normal steady state of a pluripotent stem cell. Some biomedical scientists try hard to design some simpler stem-cell methods. Applying a subset of the 4 proteins provides a new way to rejuvenate cells to a lesser degree. This new approach does not totally strip off all key negative epigenetic markers from each cell. Instead, this new approach removes only some of the apparently excessive epigenetic markers in association with old age. The resultant partial cellular rejuvenation continues to help boost cellular metabolism with virtually no or little telomere attrition, epigenetic alteration, stem cell exhaustion, cellular senescence, intercellular breakdown, and genomic instability. In essence, this new approach solves many of the 12 hallmarks of human age progression at the same time. These novel, non-obvious, and next-generation stem-cell methods continue to be an active empirical research domain for the biomedical sciences of both better healthspan and longer lifespan.

 

In the current battle against stem-cell exhaustion, the biomedical bellwethers span Altos Labs, Life Biosciences, Retro Biosciences, BlueRock Therapeutics, Lineage Cell Therapeutics, AgeX Therapeutics, AstraZeneca, and so forth. In the meantime, each of the biomedical ventures plays its cards close to its chest. The mainstream approach involves making new, non-obvious, and next-generation stem cells in the lab and then transplanting these fresh stem cells in the human body. In effect, this treatment helps rejuvenate some stem cells, molecules, tissues, and organs in situ. The medium-term and relatively transient cellular metabolism gives many old cells, tissues, and molecules a fresh capacity for self-repair and self-correction. In recent years, this fresh stem-cell treatment has been shown to be effective for nerve fibers, eyes, hearts, livers, kidneys, and pancreases. Also, this fresh stem-cell treatment even helps ameliorate the loss of long-term memory. The next targets for the stem-cell treatment include Alzheimer’s and Parkinson’s diseases. In sum, these stem-cells methods can help hone high-efficacy medications, treatments, and therapies for heart diseases, diabetes, liver and kidney diseases, some sorts of cancers, and almost all kinds of cell impairments. In due course, the new, non-obvious, and next-generation stem-cell methods often help slow down and even reverse some parts, aspects, and components of human age progression.

 

In terms of genomic revitalization, there are often several DNA costs, benefits, and trade-offs for biomedical scientists to evaluate in cell rejuvenation specifically, and human age progression more generally.

Many types of cells retain repair and surveillance mechanisms to correct damage to their genes, proteins, amino acid chains, and DNA sequences. Mutations persist in some special cases because evolution makes these protective mechanisms only good enough but often far from perfect. The hefty investment for complete vital cell rejuvenation would often cost the cell more than the DNA damage from mutations. When we place cells in the broader environment where one sort of damage to DNA sequences becomes more common, these cells give up on repairing several other sorts of genes, proteins, amino acid chains, and DNA sequences. In this alternative steady state, the desirable DNA repairs would not be worthwhile. Hence, there are often many DNA costs, benefits, and trade-offs for biomedical scientists to assess in cell rejuvenation specifically, and human age progression more generally.

 

The biggest health risk sometimes arises from bad molecular mutations, and these mutations unleash and unbridle the cell’s innate capacity to reproduce with neither pause nor purpose. As a consequence, these mutations cause cancer. In response, the human body activates tumor-repressive proteins, amino acid chains, and DNA sequences. Also, there are various ways for the immune system to swoop on those cells with bad mutations. As a major backstop, the Hayflick limit gives cells only so many chances to reproduce themselves.

 

Here, biomedical scientists weigh, assess, and evaluate many DNA costs, benefits, and trade-offs in association with human cell rejuvenation specifically, and human age progression more generally. Should some sort of biomedical intervention relax anti-cancer measures, natural human age progression might be less of a problem. There would be substantially less activity in tumor-repressive proteins, amino acid chains, and DNA sequences. As a result, there would be substantially less damage due to cellular senescence. In response to cancer, substantially greater activity in tumor-repressive proteins, amino acid chains, and DNA sequences would leak into some other parts of the human body. In effect, this greater activity would probably cripple any nearby stem cells. The clear and present trade-offs prevail in the sense that cell revitalization might inadvertently offset the slow erosion of bad mutations. Specifically, the hard and hefty price of revitalizing old cells for further growth would be more cancerous cells. Hence, cell rejuvenation might help spread cancer faster than the new normal steady state. For this reason, biomedical scientists often need to assess many different genomic costs, benefits, and trade-offs in association with human cell rejuvenation specifically, and human age progression more generally. With substantial uncertainty around the treatment efficacy of stem-cell rejuvenation, there is no easy answer.

 

In recent years, biomedical scientists seek to apply mRNA technology to help cells extend their telomeres to avoid the Hayflick limit. These biomedical scientists think telomere attrition can be kept to a minimum with several mRNA adjustments if cells make more of a vital component of telomerase. These biomedical scientists would inject mRNA into cells, tissues, and molecules for better rejuvenation. As a result, these cells, tissues, and molecules would then gain some short-run ability to make more of this vital substance of telomerase. In some recent lab studies, pepping up telomerase experimentally increases both better healthspan and longer lifespan of mice with significant positive effects on insulin response, neurological function, and physical strength. With respect to this unique strand of mRNA biomedical research, the key targets are liver fibrosis, cirrhosis, chronic inflammation, and mitochondrion dysfunction, the latter of which are 2 of the 12 hallmarks of human age progression. We believe the resultant new mRNA biomedical research endeavors can come to fruition in time.

 

Another nexus between mitochondrion dysfunction and human longevity arises in the form of humanins or some short amino acid chains also known as peptides. In addition to containing genes with full-size proteins, mitochondrial genomes further contain lots of short DNA sequences in support of substantially more peptides and humanins. As people age, humanins normally become less prevalent in the human body. Some recent studies of centenarians show that their vital levels of humanins stay high. Additional lab experiments show that nematode worms with new genetic modifications of high levels of humanins often tend to live longer. As a result, many biomedical researchers believe these new state-of-the-art genetic modifications of higher levels of humanins can play a vital role in the treatments of Alzheimer’s and Parkinson’s diseases, diabetes, obesity, and chronic inflammation.

 

A cell’s machine is made almost entirely of proteins, or some chains of amino acids when they fold into some particular shapes. These specific shapes help recognize many other molecules, and sometimes these shapes combine different molecules together with better biochemical chain reactions. Other shapes and their resultant biochemical chain reactions help cut DNA, RNA, or several other protein molecules into chunks. Long thin ones fit together to create the rods and filaments in support of the broader cell structure’s complete cytoskeleton. Also, some other shapes and their chain reactions help make pores in membranes in many other parts, aspects, and components of the human body. With extant help and support from amino acid chains, each protein has to fold into the correct shape for some vital function.

 

Sometimes bad gene mutations can cause some protein to interact with the wrong amino acid chains in one of more positions. As a result, some protein folds into the wrong shape by mistake. When the resultant protein reproduces in vast quantities, its subsequent progenitor proteins not only cause dysfunction in cells, tissues, and molecules, but also overwhelm the cellular repair mechanisms. In this rare special case, the bad gene mutations lead to genomic instability, proteostasis loss, chronic inflammation, autophagy decline, dysbiosis, cellular senescence, and intercellular breakdown, at least 7 of the 12 hallmarks of human age progression.

 

Proteostasis is the vital internal process that supplies many different cells with the right proteins in the right proportions in peak tip-top conditions. Bad gene mutations may cause impairment in self-corrective control over this vital process. When vast amounts of proteins fold into the wrong shapes, this luckless outcome often leads to the loss of proteostasis. Many biomedical studies and lab experiments show that the gradual accumulation of proteins in the wrong shapes may eventually result in diseases, disorders, and other health conditions in association with old age. These ailments span Alzheimer’s and Parkinson’s diseases, chronic inflammation, retinal degeneration, diabetes, and cataracts etc.

 

Many medical scientists focus on micro-autophagy as a vital self-repair mechanism for cell rejuvenation. In effect, micro-autophagy helps clear away bad proteins and amino acid chains in the wrong shapes. In addition to epigenetic alteration, micro-autophagy repairs many bits and pieces of cell machinery, disassemble them, and then recycle the resultant amino acid chains as vital energy reserves. Specifically, genetic stimulation of autophagy slows down and even reverses the natural course of human age progression in some rare special cases. In several recent biomedical studies and lab experiments, genetic alteration and micro-autophagy can combine to help substantially improve both better healthspan and longer lifespan in lab rats, dogs, fruit flies, and nematode worms. In recent years, the new anti-obesity weight-loss medication for diabetes, Metformin, also helps boost autophagy in new clinical trials. The key brain pathways that regulate cells in accordance with the amino acid energy available might further help remove bad proteins in the wrong shapes.

 

Another one of the 12 hallmarks of human age progression is chronic inflammation. Healthy inflammation is a vital response to common damage in cells, tissues, and molecules, as a result of pathogens, parasites, or both. White blood cells help heed better biochemical interactions to clear out sick cells. In essence, these white blood cells swoop in to clear out the sick cells, and sometimes bad proteins, to fight back against the invaders. A side-effect of these biochemical chain reactions is that they cause some nearby cells to swell. Swollen cells increase internal pressure in some parts, aspects, and components of the human body.

 

In due course, genetic instability, cellular senescence, and intercellular breakdown combine to cause poor communications with their microbiome (dysbiosis), release swollen cells, and then provoke severe inflammatory responses in some vital parts, aspects, and components of the human body. As a sound indicator of inflammation, a high level of Interleukin-6 (IL-6) bioactive protein is significantly predictive of all-cause mortality in humans. To keep chronic inflammation to a minimum, we should sustain lean and healthy lifestyle changes such as good diet, regular exercise, and high-quality sleep.

 

As an early advocate for Sirtuins and Resveratrol, Harvard biomedical scientist Dr David Sinclair cofounds the New York health startup, Tally Health, whose premium members get regular cheek-swab tests from quarter to quarter to check their levels of epigenetic methylation. These tests help measure each member’s biological age, by comparison to her calendar age. Also, Tally Health provides their members with daily health supplements such as Resveratrol, Fisetin, Quercetin, Spermidine, and Alpha-Ketoglutarate. In essence, these health supplements help heal many of the 12 hallmarks of human age progression. As a result, their daily consumption helps improve substantially better healthspan and longer lifespan. For more substantial fees, Human Longevity allows customers to access the complete classification and categorization of their respective DNA profiles with additional biometric body scans, blood tests, and cell therapies etc. In practice, Human Longevity helps personalize the action plans for its customers to live longer lives. Some epigenetic manipulation combines with cell rejuvenation to help slow down and reverse the natural pace of human age progression. At the margin, these recent ventures strive to extend their average customer lifespan by more than one year every year. Today, there is some serious interest in the biological root causes of human age progression, specifically, the mainstream 12 hallmarks of human age progression. We believe some further clinical trials, studies, and experiments can come to fruition with significantly bigger breakthroughs in time. In recent years, several tech titans and billionaires reshape and sometimes disrupt pharmaceutical investments for both better healthspan and longer lifespan worldwide.

 

AYA macro tech analytic report on the new integration of artificial intelligence (AI) into medications, treatments, and therapies worldwide

https://ayafintech.network/blog/the-new-integration-of-artificial-intelligence-reshapes-the-competitive-landscape-for-the-global-market-for-better-medical-innovations-and-healthcare-services/

 

AYA macro tech analytic report on the global market for GLP-1 anti-obesity weight-loss medications

https://ayafintech.network/blog/the-global-market-for-GLP-1-weight-loss-medications-grows-substantially-to-benefit-1-billion-people-worldwide-by-2030/

 

AYA Stock Synopsis: Pharmaceutical post-pandemic patent development cycle

https://ayafintech.network/blog/stock-synopsis-pharmaceutical-post-pandemic-patent-development-cycle/

 

AYA stock page for Grail ($GRAL):

https://ayafintech.network/stock/GRAL/

 

AYA stock page for Bristol-Myers Squibb ($BMY) and Juno Therapeutics:

https://ayafintech.network/stock/BMY/

 

AYA stock page for Unity Biotechnology ($UBX):

https://ayafintech.network/stock/UBX/

 

AYA stock page for Quantum Biosciences ($QNTM):

https://ayafintech.network/stock/QNTM/

 

AYA stock page for Ginkgo Bioworks ($DNA):

https://ayafintech.network/stock/DNA/

 

AYA stock page for GlaxoSmithKline ($GSK) and its lean subsidiary Sirtris:

https://ayafintech.network/stock/GSK/

 

AYA stock page for Lineage Cell Therapeutics ($LCTX):

https://ayafintech.network/stock/LCTX/

 

AYA stock page for AgeX Therapeutics ($AGE):

https://ayafintech.network/stock/AGE/

 

AYA stock page for AstraZeneca ($AZN):

https://ayafintech.network/stock/AZN/

 

AYA stock page for Butterfly ($BFLY):

https://ayafintech.network/stock/BFLY/

 

AYA stock page for Celldex ($CLDX) and its AI-driven research arm CuraGen:

https://ayafintech.network/stock/CLDX/

 

AYA stock page for Hyperfine ($HYPR):

https://ayafintech.network/stock/HYPR/

 

AYA stock page for Schrodinger ($SDGR):

https://ayafintech.network/stock/SDGR/

 

AYA stock page for Nuance Health ($NUAN):

https://ayafintech.network/stock/NUAN/

 

AYA stock page for Novo Nordisk ($NVO):

https://ayafintech.network/stock/NVO/

 

AYA stock page for Eli Lilly ($LLY):

https://ayafintech.network/stock/LLY/

 

AYA stock page for Pfizer ($PFE):

https://ayafintech.network/stock/PFE/

 

AYA stock page for AbbVie ($ABBV):

https://ayafintech.network/stock/ABBV/

 

AYA stock page for Merck ($MRK):

https://ayafintech.network/stock/MRK/

 

AYA stock page for Amgen ($AMGN):

https://ayafintech.network/stock/AMGN/

 

AYA stock page for Johnson & Johnson ($JNJ):

https://ayafintech.network/stock/JNJ/

 

AYA stock page for Palantir Technology ($PLTR):

https://ayafintech.network/stock/PLTR/

 

AYA stock page for Alphabet Google ($GOOGL):

https://ayafintech.network/stock/GOOGL/

 

AYA stock page for Alphabet Google ($GOOG):

https://ayafintech.network/stock/GOOG/

 

AYA stock page for Meta Facebook ($META):

https://ayafintech.network/stock/META/

 

AYA stock page for Amazon ($AMZN):

https://ayafintech.network/stock/AMZN/

 

AYA stock page for Microsoft ($MSFT):

https://ayafintech.network/stock/MSFT/

 

 

As of mid-2026, we provide our proprietary dynamic conditional alphas for the U.S. top tech titans Meta, Apple, Microsoft, Google, and Amazon (MAMGA). Our unique proprietary alpha stock signals enable both institutional investors and retail traders to better balance their key stock portfolios. This delicate balance helps gauge each alpha, or the supernormal excess stock return to the smart beta stock investment portfolio strategy. This proprietary strategy minimizes beta exposure to size, value, momentum, asset growth, cash operating profitability, and the market risk premium. Our unique proprietary algorithmic system for asset return prediction relies on U.S. trademark and patent protection and enforcement.

1. 11.18% 6-factor dynamic conditional alpha for Meta;
2. 11.25% 6-factor dynamic conditional alpha for Apple;
3. 11.60% 6-factor dynamic conditional alpha for Microsoft;
4. 11.55% 6-factor dynamic conditional alpha for Google; and
5. 11.15% 6-factor dynamic conditional alpha for Amazon.

 

Our unique algorithmic system for asset return prediction includes 6 fundamental factors such as size, value, momentum, asset growth, profitability, and market risk exposure.

 

Our proprietary alpha stock investment model outperforms the major stock market benchmarks such as S&P 500, MSCI, Dow Jones, and Nasdaq. We implement our proprietary alpha investment model for U.S. stock signals. A comprehensive model description is available on our AYA fintech network platform. Our U.S. Patent and Trademark Office (USPTO) patent publication is available on the World Intellectual Property Office (WIPO) official website.

 

Our core proprietary algorithmic alpha stock investment model estimates long-term abnormal returns for U.S. individual stocks and then ranks these individual stocks in accordance with their dynamic conditional alphas. Most virtual members follow these dynamic conditional alphas or proprietary stock signals to trade U.S. stocks on our AYA fintech network platform. For the recent period from February 2017 to February 2024, our algorithmic alpha stock investment model outperforms the vast majority of global stock market benchmarks such as S&P 500, MSCI USA, MSCI Europe, MSCI World, Dow Jones, and Nasdaq etc.

 

With U.S. fintech patent approval, accreditation, and protection for 20 years, our AYA fintech network platform provides proprietary alpha stock signals and personal finance tools for stock market investors worldwide.

We build, design, and delve into our new and non-obvious proprietary algorithmic system for smart asset return prediction and fintech network platform automation. Unlike our fintech rivals and competitors who chose to keep their proprietary algorithms in a black box, we open the black box by providing the free and complete disclosure of our U.S. fintech patent publication. In this rare unique fashion, we help stock market investors ferret out informative alpha stock signals in order to enrich their own stock market investment portfolios. With no need to crunch data over an extensive period of time, our freemium members pick and choose their own alpha stock signals for profitable investment opportunities in the U.S. stock market.

Smart investors can consult our proprietary alpha stock signals to ferret out rare opportunities for transient stock market undervaluation. Our analytic reports help many stock market investors better understand global macro trends in trade, finance, technology, and so forth. Most investors can combine our proprietary alpha stock signals with broader and deeper macro financial knowledge to win in the stock market.

Through our proprietary alpha stock signals and personal finance tools, we can help stock market investors achieve their near-term and longer-term financial goals. High-quality stock market investment decisions can help investors attain the near-term goals of buying a smartphone, a car, a house, good health care, and many more. Also, these high-quality stock market investment decisions can further help investors attain the longer-term goals of saving for travel, passive income, retirement, self-employment, and college education for children. Our AYA fintech network platform empowers stock market investors through better social integration, education, and technology.

 

This analytic essay cannot constitute any form of financial advice, analyst opinion, recommendation, or endorsement. We refrain from engaging in financial advisory services, and we seek to offer our analytic insights into the latest economic trends, stock market topics, investment memes, personal finance tools, and other self-help inspirations. Our proprietary alpha investment algorithmic system helps enrich our AYA fintech network platform as a new social community for stock market investors: https://ayafintech.network.

We share and circulate these informative posts and essays with hyperlinks through our blogs, podcasts, emails, social media channels, and patent specifications. Our goal is to help promote better financial literacy, inclusion, and freedom of the global general public. While we make a conscious effort to optimize our global reach, this optimization retains our current focus on the American stock market.

This free ebook, AYA Analytica, shares new economic insights, investment memes, and stock portfolio strategies through both blog posts and patent specifications on our AYA fintech network platform. AYA fintech network platform is every investor's social toolkit for profitable investment management. We can help empower stock market investors through technology, education, and social integration.

We hope you enjoy the substantive content of this essay! AYA!

 

Andy Yeh

Co-Chair

Brass Ring International Density Enterprise (BRIDE) © 

 

Do you find it difficult to beat the long-term average 11% stock market return?

It took us 20+ years to design a new profitable algorithmic asset investment model and its attendant proprietary software technology with fintech patent protection in 2+ years. AYA fintech network platform serves as everyone's first aid for his or her personal stock investment portfolio. Our proprietary software technology allows each investor to leverage fintech intelligence and information without exorbitant time commitment. Our dynamic conditional alpha analysis boosts the typical win rate from 70% to 90%+.

Our new alpha model empowers members to be a wiser stock market investor with profitable alpha signals! The proprietary quantitative analysis applies the collective wisdom of Warren Buffett, George Soros, Carl Icahn, Mark Cuban, Tony Robbins, and Nobel Laureates in finance such as Robert Engle, Eugene Fama, Lars Hansen, Robert Lucas, Robert Merton, Edward Prescott, Thomas Sargent, William Sharpe, Robert Shiller, and Christopher Sims.

 

Follow our Brass Ring Facebook to learn more about the latest financial news and fantastic stock investment ideas: http://www.facebook.com/brassring2013.

 

Follow AYA Analytica financial health memo (FHM) podcast channel on YouTube: https://www.youtube.com/channel/UCvntmnacYyCmVyQ-c_qjyyQ

 

Free signup for stock signals: https://ayafintech.network  

Mission on profitable signals: https://ayafintech.network/mission.php 

Model technical descriptions: https://ayafintech.network/model.php

Blog on stock alpha signals: https://ayafintech.network/blog.php

Freemium base pricing plans: https://ayafintech.network/freemium.php 

Signup for periodic updates: https://ayafintech.network/signup.php

Login for freemium benefits: https://ayafintech.network/login.php